A study co-authored by CU Cancer Center member Dr. Andrew Kent, reveals that the inflammasome, a group of immune proteins, protects blood stem cells from becoming cancerous by regulating receptors and suppressing oncogene activity. These findings highlight the inflammasome's dual role in both promoting inflammation in late-stage cancer and preventing malignancy during early stages.